Show simple item record

Genetic Mutations and Ubiquitination in Melanoma Growth and Metastasis

dc.contributor.author Zhang, Jennifer
dc.contributor.author Dikshit, Anushka
dc.date.accessioned 2019-02-01T15:12:11Z
dc.date.available 2019-02-01T15:12:11Z
dc.date.issued 2019-11-08
dc.identifier.uri https://hdl.handle.net/10161/17986
dc.description.abstract Upon neoplastic transformation, melanoma is intrinsically prone to metastasis, which marks the most dangerous aspect of the disease and dubs it one of the most challenging cancers to treat. BRAF/MEK oncokinase inhibitors and immunotherapies have shown considerable promise in some patients, but the clinical benefits are often short-lived due to rapid development of resistance. Recently, ubiquitination enzymes have emerged as potential therapeutic targets. These enzymes can be targeted to increase expression of tumor suppressors and impede activation of oncogenic signaling pathways mediating cell proliferation and tissue invasion. This chapter describes some of the common genetic mutations in melanoma, ubiquitinating and deubiquitinating enzymes that are linked to melanoma progression, metastasis, and therapeutic resistance.
dc.publisher IntechOpen
dc.title Genetic Mutations and Ubiquitination in Melanoma Growth and Metastasis
dc.type Book section
duke.contributor.id Zhang, Jennifer|0380897
dc.date.updated 2019-02-01T15:12:10Z
pubs.begin-page 125
pubs.end-page 141
pubs.organisational-group School of Medicine
pubs.organisational-group Duke
pubs.organisational-group Duke Cancer Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Dermatology
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Pathology
pubs.publisher-url https://www.intechopen.com/books/cancer-metastasis/genetic-mutations-and-ubiquitination-in-melanoma-growth-and-metastasis


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record